Concerted deletions eliminate a neutralizing supersite in SARS-CoV-2 BA.2.87.1 spike.
Duyvesteyn HME. et al, (2024), Structure (London, England : 1993), 32, 1594 - 1602.e6
Immunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: A prospective observational study in Vietnam
Thanh TT. et al, (2024), International Journal of Infectious Diseases, 147, 107173 - 107173
Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibition
(2024), Proceedings of the National Academy of Sciences, 121
A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity
Liu C. et al, (2024), Cell Reports Medicine, 5, 101553 - 101553
Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection.
Liu C. et al, (2024), Nature communications, 15
The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86.
Zhou D. et al, (2024), Nature communications, 15
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses
Dijokaite-Guraliuc A. et al, (2023), Cell Reports, 42, 112271 - 112271
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75
Huo J. et al, (2023), Cell Reports, 42, 111903 - 111903
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Tuekprakhon A. et al, (2022), Cell, 185, 2422 - 2433.e13
Flavivirus maturation leads to the formation of an occupied lipid pocket in the surface glycoproteins
Renner M. et al, (2021), Nature Communications, 12
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Flaxman A. et al, (2021), The Lancet, 398, 981 - 990
The antigenic anatomy of SARS-CoV-2 receptor binding domain
Dejnirattisai W. et al, (2021), Cell, 184, 2183 - 2200.e22
Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice.
Salazar V. et al, (2019), Cell reports, 26, 1585 - 1597.e4
Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine
Tsai W-Y. et al, (2018), Journal of Virology, 92
Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors
López-Camacho C. et al, (2018), Nature Communications, 9
Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus
Renner M. et al, (2018), Nature Immunology, 19, 1248 - 1256
The immune response against flaviviruses
Slon Campos JL. et al, (2018), Nature Immunology, 19, 1189 - 1198
Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas
Montoya M. et al, (2018), The Journal of Infectious Diseases, 218, 536 - 545
Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys
Abbink P. et al, (2018), Nature Medicine, 24, 721 - 723
Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?
Screaton G. and Mongkolsapaya J., (2018), Cold Spring Harbor Perspectives in Biology, 10, a029520 - a029520